TVI’s mission is to identify, help create and support the development of therapeutic innovation that aligns with Takeda’s own strategic imperatives. We do this by investing in technology and product concepts, and highly effective teams that can turn ideas into reality. Our primary focus is on medium to longer term returns in the form of product and technology successes for our portfolio companies and capital gains for the financial institutions we work with. As a Pharma strategic investor, TVI aims to provide support and guidance to entrepreneurs and early-stage companies driving concepts from preclinical through clinical proof of concept. We also strive to forge active, collaborative interactions that result in synergies with Takeda’s considerable R&D resources. TVI is based in Palo Alto, California and is actively seeking global investment opportunities. Our goal is to build a portfolio of strategic investments, with an immediate emphasis on cardiometabolic, central nervous system, chronic inflammatory and immune modulation, and oncology therapeutic domains. Our focus also includes new platforms for drug target and biomarker identification, regenerative medicines, innovative vaccines technologies and delivery systems for novel protein and peptide therapeutics. TVI currently does not invest in diagnostics platforms, medical technology and devices or anti-infective products.
|Hookipa Biotech||11/2013||Series B||€20M||5|
|Heptares Therapeutics||6/2013||Series B||$21M||2|
|ArmaGen Technologies||11/2012||Series A||$17M||4|
|Juventas Therapeutics||7/2012||Series B||$22.2M||8|
|Redwood Bioscience||6/2011||Venture Round||1|
|Lectus Therapeutics||2/2006||Series A||£8.2M||4|